Kinnate Biopharma increases IPO size by 25% to $213M

 

• Kinnate Biopharma (KNTE) has raised the proposed deal size for its upcoming IPO.
• The company now plans to raise $213M by offering 11.5M shares at a price range of $18 to $19 vs. original offering of 10M shares at a range of $16 to $18.
• Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead candidate, KIN002787, is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors. The company expects to file an IND for KIN002787 in the 1H21.
• https://seekingalpha.com/news/3640795-kinnate-biopharma-increases-ipo-size-25-to-213m